Regeneron Pharmaceuticals is a biotech company that develops and sells medicines for various diseases. The company has been making headlines recently for its innovative products, such as REGEN-COV for COVID-19, Dupixent for allergic and inflammatory diseases, and Libtayo for various cancers. These products have helped Regeneron achieve impressive revenue growth, profitability, and market share in the highly competitive biotech industry.

Regeneron Pharmaceuticals's Overview

Source: Alamy

What is Regeneron

Regeneron Pharmaceuticals was founded in 1988 by Leonard Schleifer and George Yancopoulos in Tarrytown, New York, where it remains headquartered today. Regeneron has four main segments: Research and Development (R&D), Commercial, Industrial Operations and Product Supply (IOPS), and Corporate.

  • The R&D segment discovers and develops new drugs and technologies, such as monoclonal antibodies, gene therapies, and bispecific antibodies.
  • The Commercial segment markets and sells the approved drugs in the U.S. and collaborates with global partners, such as Sanofi and Bayer.
  • The IOPS segment manufactures and supplies the drugs to customers and partners.
  • The Corporate segment provides support functions, such as finance, legal, human resources, and information technology.

Regeneron CEO

The current CEO of Regeneron is Leonard Schleifer, who is also the co-founder and co-chair of the board of directors. Schleifer is a physician-scientist with a medical degree and a Ph.D. from the University of Virginia. He has been leading Regeneron since its inception and has overseen the development and launch of several blockbuster drugs, such as EYLEA, Dupixent, Libtayo, and REGEN-COV.

The top shareholders of Regeneron are Sanofi, Fidelity Management & Research Co., The Vanguard Group Inc., BlackRock Fund Advisors, and Capital Research & Management Co. Sanofi is also a strategic partner of Regeneron, as they have collaborated on several drugs, such as Dupixent, Libtayo, Praluent, Kevzara, and Zaltrap.

Regeneron has achieved several milestones and innovations since its inception in 1988. The company received its first FDA approval for Arcalyst in 2008. Since then, it has launched several blockbuster drugs, such as EYLEA (2011), Praluent (2015), Dupixent (2017), Libtayo (2018), and REGEN-COV (2020).

Regeneron Pharmaceuticals's Business Model and Products/Services

Source: Alamy

Regeneron Pharmaceuticals makes money in three ways: product sales, collaboration revenues, and technology licensing revenues. Product sales are the revenues generated from selling approved drugs in the U.S. and other markets. Collaboration revenues are from partnering with other companies, such as Sanofi and Bayer, to develop and commercialize its drugs globally. Technology licensing revenues are from granting access to its proprietary technologies, such as VelociSuite®, to other companies, such as Sanofi and Astellas.

Regeneron Products

Regeneron Pharmaceuticals has three main products: EYLEA, Dupixent, and Libtayo. EYLEA is a drug for various eye diseases. Dupixent is a drug for various allergic and inflammatory diseases. Libtayo is a drug for various types of cancers. Regeneron Pharmaceuticals also has an authorized product for emergency use: REGEN-COV, a combination of two monoclonal antibodies that can prevent and treat COVID-19.

Regeneron Pharmaceuticals's Financials, Growth, and Valuation Metrics

Regeneron Pharmaceuticals has a strong financial performance and growth potential.

Regeneron Market Cap

The company has a market capitalization of $81.95 billion as of July 27, 2023, making it one of the largest biotech companies in the world.

Regeneron Earnings

The company had a net income of $818 million in Q1 2023, down 16% from Q1 2022, mainly due to a one-time charge of $172 million for its collaboration with Alnylam Pharmaceuticals. The company's total revenues grew by 7% to $3.16 billion in Q1 2023, driven by a 9% increase in product sales to $2.04 billion and a 4% increase in collaboration revenues to $1.12 billion. The company's technology licensing revenues decreased by 19% to $4 million in Q1 2023. The company's gross profit margin was 66.8%, operating profit margin was 38.1%, and net profit margin was 33.8% in Q1 2023, all lower than Q1 2022. The company's ROE was 19.3% in Q1 2023, also lower than Q1 2022, indicating lower profitability.

The company had a strong balance sheet and liquidity position in Q1 2023, with a net cash of $6.26 billion and a debt-to-equity ratio of 11.5%. The company's valuation multiples were lower than its peers and the industry, suggesting an undervalued stock. The company's P/E ratio was 19.26, lower than its peers' average of 25.67 and the industry's average of 24.02. The company's P/S ratio was 6.51, lower than its peers' average of 9.55 and the industry's average of 8.22. The company's P/B ratio was 3.31, lower than its peers' average of 4.88 and the industry's average of 4.46. The company's EV/EBITDA ratio was 13.97, lower than its peers' average of 18.64 and the industry's average of 17.47. However, the company's growth rates were also lower than its peers and the industry, implying less growth potential. The company's revenue growth rate was 6.60% and earnings growth rate was -16% in Q1 2023, both lower than the averages of its peers (12.15% and 10.85%) and the industry (10.97% and 9.35%).

REGN Stock Performance Analysis

REGN stock is the ticker symbol for Regeneron Pharmaceuticals, a biotech company that develops and sells medicines for various diseases. The stock trades on the NASDAQ stock exchange and is majorly in U.S. dollars. The stock was first listed on NASDAQ in 1991 at an initial public offering (IPO) price of $22 per share. The stock trading hours are from 9:30 a.m. to 4:00 p.m. Eastern Time on weekdays, with pre-market trading from 4:00 a.m. to 9:30 a.m. and after-market trading from 4:00 p.m. to 8:00 p.m. The stock has never split or paid any dividends.

REGN stock has performed well since its IPO, reaching several historical highs and lows. The stock reached its all-time high of $833.62 on April 17, 2023. The stock reached a 52-week low of $569.65, 22.1% below the current price. As of July 27, 2023, the stock closed at $745.81, up 1.91% from the previous day.

REGN stock has been volatile in the past year, fluctuating between $587.91 and $744.90. The various factors that have influenced Regeneron stock price include:

  • Regeneron News like the company's financial results and guidance, which have shown strong revenue growth and profitability, get driven by its main products: EYLEA, Dupixent, and Libtayo.
  • The company's product pipeline and R&D activities have demonstrated innovation and potential in developing new therapies for unmet medical needs, such as COVID-19, cancer, eye disorders, infectious diseases, and inflammatory conditions.
  • The company's collaborations and partnerships with other companies, such as Sanofi, Bayer, Alnylam Pharmaceuticals, Intellia Therapeutics, and Decibel Therapeutics, which have expanded its market reach and enhanced its technology capabilities.
  • The company's competitive risks and regulatory uncertainties, which have posed challenges and threats to its market position and product approvals, such as competition from other biotech giants like Amgen, Gilead Sciences, Vertex Pharmaceuticals, etc., patent expirations and litigation for some of its products like EYLEA and Praluent, and potential changes in drug pricing and reimbursement policies under the new U.S. administration.

REGN Stock Forecast

REGN stock price forecast has its basis on various sources of analysis, like trend analysis, technical analysis, and analyst recommendations and price targets. Based on these sources, REGN stock price should:

  • Follow an upward trend in the long-term as the company continues to grow its revenues and earnings, launch new products and indications, and leverage its R&D capabilities and collaborations.
  • Face some resistance and support levels in the short term, as the stock price reacts to market fluctuations and news events. Some of the key resistance levels are $801, $837, and $795, while some of the key support levels are $668, $725, and $685.
  • Receive primarily positive ratings from analysts, who have an average consensus of buy for REGN stock. Out of 26 analysts covering REGN stock, 13 have a buy rating, 3 have an outperform rating, 8 have a hold rating, and 2 have an underperforming rating. The average price target for REGN stock is $875, with a high of $1045 and a low of $650. This implies an upside potential of 17.33% from the current stock price of $745.77.

Challenges and Opportunities

Regeneron faces several challenges and opportunities in its business, such as:

Competitive Risks

Regeneron competes with other biotech companies that have similar or superior products, technologies, and resources. Some of its main competitors are Amgen, Gilead Sciences, Vertex Pharmaceuticals, Roche, Novartis, and Pfizer. For example, Regeneron's EYLEA faces competition from Roche's Lucentis and Novartis' Beovu for treating eye diseases. Regeneron's Dupixent faces competition from Pfizer's Abrocitinib and Eli Lilly's Olumiant for treating atopic dermatitis. Regeneron's Libtayo faces competition from Merck's Keytruda and Bristol Myers Squibb's Opdivo for treating various cancers.

To overcome these competitive threats, Regeneron needs to leverage its competitive advantages, such as its innovative R&D capabilities, its proprietary VelociSuite technologies, its diversified product portfolio and pipeline, its strategic collaborations and partnerships, and its strong financial performance and growth potential.

Other Risks

Regeneron also faces other risks that could affect its business, such as regulatory uncertainties, patent expirations and litigation, pricing and reimbursement pressures, supply chain disruptions, cybersecurity breaches, product safety issues, and global health crises such as the COVID-19 pandemic. Regeneron needs to manage these risks effectively by complying with all applicable laws and regulations, protecting its intellectual property rights, maintaining its product quality and safety standards, optimizing its supply chain and manufacturing operations, enhancing its cybersecurity measures, and responding to the changing market and customer needs.

Growth Opportunities

Regeneron has several growth opportunities that could enhance its business, such as expanding its product indications and approvals, launching new products and indications, developing next-generation therapies for unmet medical needs, advancing its oncology pipeline and strategy, leveraging its human genetics research platform, expanding its global presence and market share, and pursuing new collaborations and acquisitions.

For example, Regeneron is developing next-generation antibodies that are active against the Omicron variant of COVID-19. Regeneron is also expecting data readouts from several late-stage trials for Libtayo in combination with other therapies for various cancers. Regeneron is also exploring new indications for Dupixent in chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and food allergies. Regeneron is also advancing its earlier-stage programs in areas such as pain, inflammation, infectious diseases, rare diseases, hematology, neuroscience, and cardiometabolic diseases.

Future Outlook And Expansion

Source: Alamy

Regeneron has a positive future outlook based on its strong financial performance and growth potential. The company expects to generate revenues of $18.5 billion to $19 billion in 2023, representing a growth of 15% to 18% from 2022. The company also expects to invest $2.9 billion to $3.1 billion in R&D expenses and $1.6 billion to $1.7 billion in SG&A expenses in 2023.

The company also plans to expand its production facilities in New York with an investment of $800 million over the next six years, creating 1,500 new jobs. The company also received regulatory approvals for Libtayo in cervical cancer in Europe and Japan in June 2023. The company also plans to launch new products and indications in various markets around the world.

Why Should Traders Consider REGN Stock?

Regeneron Pharmaceuticals (REGN) is one of the leading biotech companies in the world, with a diversified portfolio of innovative medicines for various diseases. The company has been growing its revenue and earnings consistently, beating analysts' expectations in the past four quarters. REGN stock has also outperformed the broader market and the biotech sector in the past year, delivering a return of 34.5% compared to 18.7% for the S&P 500 and 21.3% for the Nasdaq Biotechnology Index.

Regeneron Pharmaceuticals has a strong pipeline and partnerships. Regeneron has over 30 new drugs and indications in clinical development, which could bring significant revenue and growth potential in the future. The company also collaborates with other biotech leaders, such as CRISPR Therapeutics, Intellia Therapeutics, and Seagen, to enhance its capabilities in gene editing and oncology, which are cutting-edge fields in biotechnology.

Trading Strategies for REGN Stock

There are different ways to trade REGN stock, depending on the trader's risk appetite, time horizon, and market outlook. Some of the possible strategies are:

Swing Trading

Swing trading is a medium-term strategy that involves holding a position in REGN stock for several days or weeks, based on technical analysis, market trends, and news events. Swing traders can use various indicators and tools, such as moving averages, trend lines, support and resistance levels, and chart patterns, to identify entry and exit points for REGN stock. For example, a swing trader might buy REGN stock when it breaks above a resistance level or a bullish chart pattern, such as a cup and handle or an ascending triangle.

Alternatively, a swing trader might sell REGN stock when it breaks below a support level or a bearish chart pattern, such as a head and shoulders or a descending triangle. Swing trading requires discipline, patience, and risk management, as well as a good understanding of the fundamentals and catalysts of REGN stock.

Source: TradingView

Options Trading

Options trading is a way of using contracts that give the buyer the right, but not the obligation, to buy or sell Regeneron stock at a specified price and date. Options can be used to hedge against price fluctuations, generate income, or speculate on directional or volatility movements of REGN stock. Options have two types: calls and puts. A call option gives the buyer the right to buy REGN stock at a certain price (called the strike price) before or on a certain date (called the expiration date). A put option gives the buyer the right to sell REGN stock at a certain price before or on a certain date.

Options have different prices (called premiums), which depend on various factors, such as the current price of REGN stock, the strike price, the expiration date, the volatility of REGN stock, and the interest rate. Options trading requires a thorough understanding of the options market, pricing models, and strategies. Some of the common options strategies are:

  • Covered Call: This involves selling a call option while owning REGN stock. This strategy generates income from the premium received from selling the call option and also provides some downside protection if REGN stock falls. However, this strategy also limits the upside potential if REGN stock rises above the strike price of the call option.
  • Protective Put: This involves buying a put option while owning REGN stock. This strategy provides insurance against a large drop in REGN stock price by allowing the owner to sell REGN stock at the strike price of the put option. However, this strategy also reduces the net profit from owning REGN stock by the amount of premium paid for buying the put option.
  • Long Straddle: This involves buying both a call option and a put option with the same strike price and expiration date on REGN stock. This strategy profits from large movements in either direction of REGN stock price by allowing the owner to exercise either the call option or the put option depending on which one is more profitable. However, this strategy also involves paying a high premium for buying both options and loses money if REGN stock price stays close to the strike price.

CFD Trading

CFD trading is a way of speculating on the price movements of Regeneron stock without actually owning the shares. CFDs are contracts that track the difference between the opening and closing prices of the underlying asset. Traders can use CFDs to go long (buy) or short (sell) REGN stock, depending on their market view. CFDs also offer leverage, which means that traders can use a small amount of capital to control a larger position.

However, leverage also magnifies the potential losses, so traders need to be careful and use stop-loss orders to limit their risk. CFD trading is suitable for traders who want to take advantage of short-term price fluctuations, as well as hedge their existing positions in REGN stock. CFD trading is not available in some countries, such as the US, due to regulatory restrictions.

Trade REGN Stock CFD with VSTAR

If you are interested in trading REGN stock CFD, you may want to consider VSTAR because the platform has several advantages for traders, such as:

  • Super low trading cost: VSTAR charges zero commission and offers competitive spreads on all instruments, helping you maximize your profits.
  • Deep liquidity: VSTAR provides reliable and fast order execution with top-tier liquidity providers, ensuring you get the best market prices and avoid slippage.
  • Lightning-fast execution: VSTAR delivers ultra-fast order execution within milliseconds, allowing you to catch trading opportunities and avoid losses.
  • Fully regulated: VSTAR is authorized and regulated by the Cyprus Securities and Exchange Commission (CySEC), a member of the Cyprus Investor Compensation Fund, and operates under the European Regulatory Framework of MiFiD II, ensuring your security and protection.
  • User-friendly app: VSTAR has an easy-to-use interface with mobile enhanced trading experience, allowing you to trade anytime, anywhere. You can also explore popular markets, access risk-free demo accounts, and enjoy live support 24/7.

To start trading REGN stock CFD with VSTAR, you just need to follow these simple steps:

  • Register an account with VSTAR using your email or phone number.
  • Verify your identity and address by uploading the required documents.
  • Deposit funds using your preferred payment method, such as Visa, Mastercard, Tether, Skrill, Neteller, SticPay, Perfect Money or international bank wire.
  • Choose REGN stock CFD from the list of instruments and open a buy or sell position according to your analysis and strategy.
  • Monitor your position and close it when you reach your desired profit or loss level.


REGN stock has been performing well in the past year, outperforming the market and its peers. There are many reasons why traders should consider investing in REGN stock, such as its solid fundamentals, growth prospects, competitive advantages, and future opportunities. If you are interested in trading REGN stock CFD with VSTAR, you can register an account today and start exploring the global markets.

*Disclaimer: The content of this article is for learning purposes only and does not represent the official position of VSTAR, nor can it be used as investment advice.